Lucid Diagnostics Inc

Stock Chart, Company Information, and Scan Results

$1(as of Aug 1, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Lucid Diagnostics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$1
Ticker SymbolLUCD
ExchangeNasdaq
SectorHealthcare
IndustryMedical Devices
Employees72
CountyUSA
Market Cap$105.9M
EBIDTA-46.9M
10-Day Moving Average1.07
P/E Ratio-1.11
20-Day Moving Average1.10
Forward P/E Ratio0.00
50-Day Moving Average1.20
Earnings per Share-1.17
200-Day Moving Average1.13
Profit Margin-3,249.76%
RSI35.15
Shares Outstanding108.2M
ATR0.07
52-Week High1.80
Volume725,182
52-Week Low0.72
Most Recent Support Level1.08
Book Value-5.4M
Most Recent Resistance Level1.11
P/B Ratio-12.79
Upper Keltner1.26
P/S Ratio16.49
Lower Keltner0.94
Debt-to-Equity Ratio1.26
Next Earnings Date08/18/2025
Cash Surplus-11.3M
Next Ex-Dividend DateUnknown

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc In Our Stock Scanner

As of Aug 01, 2025
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.